MK-8558 / Merck (MSD) - LARVOL DELTA

Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8558 Monotherapy in Anti-Retroviral-Naïve HIV-1 Infected Participants (MK-8558-002) (clinicaltrials.gov) - P1; N=21; Completed; Sponsor: Merck Sharp & Dohme Corp.; Recruiting ➔ Completed

Clinical • Monotherapy • Trial completion • Gene Therapies • Human Immunodeficiency Virus • Infectious Disease

Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8558 Monotherapy in Anti-Retroviral-Naïve HIV-1 Infected Participants (MK-8558-002) (clinicaltrials.gov) - P1; N=24; Recruiting; Sponsor: Merck Sharp & Dohme Corp.; Trial completion date: Mar 2020 ➔ Jul 2020; Trial primary completion date: Mar 2020 ➔ Jul 2020

Clinical • Monotherapy • Trial completion date • Trial primary completion date